Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
Stopped early · Phase 1/Phase 2
Conditions studied: Pancreatic Cancer
In brief
This study will analyze the effects, good and/or bad, of the drug Abraxane in combination with gemcitabine and gemcitabine with concurrent radiation therapy for patients with locally advanced pancreatic cancer that cannot be removed by surgery. All of the medications used in this study are FDA-approved for use in patients with pancreatic cancer.
Key facts
- Study ID
- NCT01693276
- Run by
- Olugbenga Olowokure
- People needed
- 3
- Starts
- 2012-09-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2015-10-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically proven carcinoma of the pancreas that is locally advanced
- ECOG performance status 0- 2
- Adequate labs
- No prior abdominal radiation therapy
- No other concurrent clinically evident malignancy, except inactive nonmelanoma skin cancer, inactive cervical cancer, or other cancer for which the patient has been disease-free for 5 years
- All disease must be encompassed within a radiotherapy portal
- Not pregnant or nursing
You may not qualify if…
- Patient has metastatic disease on radiological staging
- systemic therapy.
- Patient has known active infection with HIV, hepatitis C or hepatitis B
- Patient has serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug.
- Patient is deemed to be have obvious resectable disease at presentation
- Received any investigational agent within a month prior to enrollment.
- Neuroendocrine tumors of the pancreas
Where it is running
- University of Cincinnati — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.